Patterson Cos' Strong Q4 Earnings and Intel's Strategic Sale Shake the Market
- June 21st, 2023
- 357 views
Patterson Companies, Inc. (Nasdaq: PDCO), a leading provider of products and services to the dental, animal health, and rehabilitation markets, announced strong fourth-quarter fiscal 2023 earnings. The company reported earnings per share (EPS) of $0.84, surpassing the consensus estimate of $0.70.
Looking ahead to its full-year fiscal 2024, Patterson Companies expects continued growth and anticipates adjusted EPS to be in the range of $2.45 to $2.55. This outlook also exceeds market expectations, with the consensus estimate for the period at $2.34.
In pre-market, $PDCO is currently trading at $31.59, experiencing a notable increase of $3.33 (+11.78%)
In other news, Intel Corporation (Nasdaq: INTC) has announced an agreement to sell a 20% stake in its IMS Nanofabrication GmbH (IMS) business to Bain Capital Special Situations.
This transaction values IMS at approximately $4.3 billion and is expected to be completed in the third quarter of 2023. Following the sale, IMS will operate as a separate subsidiary and will continue to be led by CEO Dr. Elmar Platzgummer.
This strategic move by Intel aims to accelerate the advancement of critical multi-beam mask writing tools and foster greater collaboration across industries. Multi-beam mask writing tools play a vital role in the semiconductor ecosystem, particularly in the development of Extreme Ultraviolet (EUV) technology.
$INTC is trading at $34.75 in pre-market, down $0.25 (0.71%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Johnson & Johnson, Charles Schwab, Halliburton: Earnings Preview
January 18th, 2026Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026




Member Login